RX Biosyent Inc

BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) announced today that it has been
selected to present at the first ever MicroCapClub Invitational. 


The presentation can be accessed at the following link:
http://microcapclub.com/2013/02/microcapclub-invitational-biosyent-rx-v/.


"At MicroCapClub we have over 170 experienced microcap investors discussing over
90 microcap companies in our members forum, and we thought as a group it would
be great to showcase a few companies we believe are highly unique," said Ian
Cassel, founder of MicroCapClub. "We have been following BioSyent for about a
year and have been impressed with the company's profitable growth trajectory.
BioSyent's strategy to in-license certain niche pharmaceutical products and
distribute them in Canada has proven to be very successful. We look forward to
following the company's progress in 2013 and beyond as they market and
distribute additional products."


"At BioSyent we are excited about our business," said Rene Goehrum, President
and CEO of BioSyent Inc. "We are pleased with our results over the last 2 1/2
years, the foundation that we have built, and our prospects for continued
growth. We look forward to sharing our continuing progress with investors as
2013 unfolds."


About MicroCapClub: The MicroCapClub (mc2) is an exclusive microcap forum
focused on microcap companies (sub $300m market cap). The MicroCapClub was
created and founded by Ian Cassel as a way to share ideas and to learn from
other seasoned like-minded microcap investors. Our goal at MicroCapClub is
quality membership and quality stock ideas. If you are an experienced microcap
investor, feel free to Apply Today. Go to www.microcapclub.com for additional
information.


BioSyent Inc. continues to concentrate on its pharmaceutical strategy to source
products that have been successfully developed and proven to be safe and
effective; manage these products through the regulatory process and product
registration (approval); and once approved, market these products in Canada. The
Company is focused on medications that occupy a niche in the market, that are
unique either due to complexity of manufacture or provide novel technological or
therapeutic advantages, or that are backed by strong partners holding
intellectual property rights that are defendable. This strategy allows the
Company to market these medications as brands owned by, or licensed to, it.


BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly
owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences
pharmaceutical products and markets these products in Canada. Wholly owned
BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy
business marketing bio and health friendly non-chemical insecticides. BioSyent
common shares are listed for trading on the TSX Venture Exchange (TSXV) under
the symbol RX.


This press release may contain information or statements that are
forward-looking. The contents herein represent our judgment, as at the release
date, and are subject to risks and uncertainties that may cause actual results
or outcomes to be materially different from the forward-looking information or
statements. Potential risks may include, but are not limited to, those
associated with clinical trials, product development, future revenue,
operations, profitability and obtaining regulatory approvals.


FOR FURTHER INFORMATION PLEASE CONTACT: 
BioSyent Inc.
Rene C. Goehrum
President and CEO
www.biosyent.com

Biosyent (TSXV:RX)
Historical Stock Chart
From May 2024 to Jun 2024

Biosyent (TSXV:RX)
Historical Stock Chart
From Jun 2023 to Jun 2024